NeuroScientific Biopharmaceuticals Ltd. announced the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB, achieving a significant milestone in the development of EmtinB as a first-in-class treatment with disease modifying potential for neurodegenerative conditions, such as Multiple sclerosis and Alzheimer's disease. The early-phase clinical trial is being undertaken by leading WA-based clinical research partner Linear Clinical Research.
NeuroScientific Biopharmaceuticals Limited
Equities
NSB
AU0000012973
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.046 AUD | +2.22% | -6.12% | +4.55% |
1st Jan change | Capi. | |
---|---|---|
+4.55% | 4.35M | |
+33.28% | 49.46B | |
+1.78% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.53% | 26.61B | |
-22.67% | 18.64B | |
+7.98% | 13.16B | |
+29.58% | 12.55B | |
+24.25% | 12.1B |
- Stock Market
- Equities
- NSB Stock
- News NeuroScientific Biopharmaceuticals Limited
- NeuroScientific Biopharmaceuticals Limited Announces Recruitment of First Subject Recruited for Early-Phase Clinical Trial